Heart failure with preserved ejection fraction

Mann, D. L., Zipes, D. P., Libby, P. & Bonow, R. O. Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine 10th edn (Elsevier/Saunders, 2015).

[2]

Heidenreich, P. A. et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 145, e895–e1032 (2022). AHA/ACC/HFSA guidelines on the diagnosis and management of HF.

[3]

Kupari, M., Lindroos, M., Iivanainen, A. M., Heikkilä, J. & Tilvis, R. Congestive heart failure in old age: prevalence, mechanisms and 4-year prognosis in the Helsinki Ageing Study. J. Intern. Med. 241, 387–394 (1997). 10.1046/j.1365-2796.1997.129150000.x

[4]

Congestive Heart Failure in the Community

Michele Senni, Christophe M. Tribouilloy, Richard J. Rodeheffer et al.

Circulation 1998 10.1161/01.cir.98.21.2282

[5]

Bursi, F. et al. Systolic and diastolic heart failure in the community. JAMA 296, 2209–2216 (2006). 10.1001/jama.296.18.2209

[6]

Trends in Prevalence and Outcome of Heart Failure with Preserved Ejection Fraction

Theophilus E. Owan, David O. Hodge, Regina M. Herges et al.

New England Journal of Medicine 2006 10.1056/nejmoa052256

[7]

Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction

Ramachandran S Vasan, Martin G Larson, ScD, Emelia J Benjamin et al.

Journal of the American College of Cardiology 1999 10.1016/s0735-1097(99)00118-7

[8]

Devereux, R. B. et al. Congestive heart failure despite normal left ventricular systolic function in a population-based sample: the Strong Heart Study. Am. J. Cardiol. 86, 1090–1096 (2000). 10.1016/s0002-9149(00)01165-6

[9]

Kitzman, D. W. et al. Importance of heart failure with preserved systolic function in patients > or = 65 years of age. CHS Research Group. Cardiovascular Health Study. Am. J. Cardiol. 87, 413–419 (2001). 10.1016/s0002-9149(00)01393-x

[10]

Gottdiener, J. S. et al. Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study. Ann. Intern. Med. 137, 631–639 (2002). 10.7326/0003-4819-137-8-200210150-00006

[11]

Bhatia, R. S. et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N. Engl. J. Med. 355, 260–269 (2006). 10.1056/nejmoa051530

[12]

Pfeffer, M. A. et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362, 759–766 (2003). 10.1016/s0140-6736(03)14282-1

[13]

Bozkurt, B. et al. Universal definition and classification of heart failure: a report of the heart failure society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. J. Card. Fail. 23, 352–380 (2021). Proposal for a universal definition of HF.

[14]

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

Theresa A McDonagh, Marco Metra, Marianna Adamo et al.

European Heart Journal 2021 10.1093/eurheartj/ehab368

[15]

2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction

Michelle M. Kittleson, Gurusher S. Panjrath, Kaushik Amancherla et al.

Journal of the American College of Cardiology 2023 10.1016/j.jacc.2023.03.393

[16]

Lam, C. S. P., Voors, A. A., Piotr, P., McMurray, J. J. V. & Solomon, S. D. Time to rename the middle child of heart failure: heart failure with mildly reduced ejection fraction. Eur. Heart J. 41, 2353–2355 (2020). 10.1093/eurheartj/ehaa158

[17]

Heart failure with mid-range or mildly reduced ejection fraction

Gianluigi Savarese, Davide Stolfo, GIANFRANCO SINAGRA et al.

Nature Reviews Cardiology 2022 10.1038/s41569-021-00605-5

[18]

Solomon, S. D. et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur. Heart J. 37, 455–462 (2016). 10.1093/eurheartj/ehv464

[19]

Kotecha, D. et al. Heart rate and rhythm and the benefit of beta-blockers in patients with heart failure. J. Am. Coll. Cardiol. 69, 2885–2896 (2017). 10.1016/j.jacc.2017.04.001

[20]

Lund, L. H. et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur. J. Heart Fail. 20, 1230–1239 (2018). 10.1002/ejhf.1149

[21]

Abdul-Rahim, A. H. et al. Effect of digoxin in patients with heart failure and mid-range (borderline) left ventricular ejection fraction. Eur. J. Heart Fail. 20, 1139–1145 (2018). 10.1002/ejhf.1160

[22]

Solomon, S. D. et al. Sacubitril/valsartan across the spectrum of ejection fraction in heart failure. Circulation 141, 352–361 (2020). 10.1161/circulationaha.119.044586

[23]

Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

Scott D. Solomon, John J.V. McMurray, Brian Claggett et al.

New England Journal of Medicine 2022 10.1056/nejmoa2206286

[24]

Paulus, W. J. Phenotypic persistence in heart failure with preserved ejection fraction. Circ. Heart Fail. 12, e005956 (2019). 10.1161/circheartfailure.119.005956

[25]

Khan, M. S., Shahid, I., Fonarow, G. C. & Greene, S. J. Classifying heart failure based on ejection fraction: imperfect but enduring. Eur. J. Heart Fail. 24, 1154–1157 (2022). 10.1002/ejhf.2470

[26]

Lam, C. S. P. & Solomon, S. D. DELIVERing therapeutic efficacy across the ejection fraction spectrum of heart failure. Circulation 146, 1193–1195 (2022). 10.1161/circulationaha.122.062022

[27]

Kondo, T. & McMurray, J. J. V. Re-emergence of heart failure with a normal ejection fraction? Eur. Heart J. 43, 427–429 (2021). 10.1093/eurheartj/ehab828

[28]

Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

Spencer L James, Degu Abate, Kalkidan Hassen Abate et al.

The Lancet 2018 10.1016/s0140-6736(18)32279-7

[29]

Epidemiology of Heart Failure

Amy Groenewegen, Frans H. Rutten, Arend Mosterd et al.

European Journal of Heart Failure 2020 10.1002/ejhf.1858

[30]

An update on global epidemiology in heart failure

Peter Moritz Becher, Lars H Lund, Andrew J S Coats et al.

European Heart Journal 2022 10.1093/eurheartj/ehac248

[31]

Thomas, M. M. et al. 2024 ACC expert consensus decision pathway for treatment of heart failure with reduced ejection fraction. J. Am. Coll. Cardiol. 83, 1444–1488 (2022).

[32]

Kapelios, C. J., Shahim, B., Lund, L. H. & Savarese, G. Epidemiology, clinical characteristics and cause-specific outcomes in heart failure with preserved ejection fraction. Card. Fail. Rev. 9, e14 (2023). 2023. 10.15420/cfr.2023.03

[33]

Epidemiology of heart failure with preserved ejection fraction

Shannon M. Dunlay, Véronique L. Roger, Margaret M. Redfield

Nature Reviews Cardiology 2017 10.1038/nrcardio.2017.65

[34]

Dokainish, H. et al. Global mortality variations in patients with heart failure: results from the International Congestive Heart Failure (INTER-CHF) prospective cohort study. Lancet Glob. Health 5, e665–e672 (2017). 10.1016/s2214-109x(17)30196-1

[35]

Ceia, F. et al. Prevalence of chronic heart failure in Southwestern Europe: the EPICA study. Eur. J. Heart Fail. 4, 531–539 (2002). 10.1016/s1388-9842(02)00034-x

[36]

Steinberg, B. A. et al. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation 126, 65–75 (2012). 10.1161/circulationaha.111.080770

[37]

Oktay, A. A., Rich, J. D. & Shah, S. J. The emerging epidemic of heart failure with preserved ejection fraction. Curr. Heart Fail. Rep. 10, 401–410 (2013). 10.1007/s11897-013-0155-7

[38]

Nochioka, K., Shiba, N., Kohno, H., Miura, M. & Shimokawa, H. Both high and low body mass indexes are prognostic risks in Japanese patients with chronic heart failure: implications from the CHART study. J. Card. Fail. 16, 880–887 (2010). 10.1016/j.cardfail.2010.06.413

[39]

Shiba, N., Nochioka, K., Miura, M., Kohno, H. & Shimokawa, H. Trend of westernization of etiology and clinical characteristics of heart failure patients in Japan — first report from the CHART-2 study. Circ. J. 75, 823–833 (2011). 10.1253/circj.cj-11-0135

[40]

Dunlay, S. M. & Roger, V. L. Understanding the epidemic of heart failure: past, present, future. Curr. Heart Fail. Rep. 11, 404–415 (2014). 10.1007/s11897-014-0220-x

[41]

Borlaug, B. A. Evaluation and management of heart failure with preserved ejection fraction. Nat. Rev. Cardiol. 17, 559–573 (2020). 10.1038/s41569-020-0363-2

[42]

Heart Failure Epidemiology and Outcomes Statistics: A Report of the Heart Failure Society of America

Biykem Bozkurt, Tariq Ahmad, Kevin M. Alexander et al.

Journal of Cardiac Failure 2023 10.1016/j.cardfail.2023.07.006

[43]

Vasan, R. S., Enserro, D. M., Beiser, A. S. & Xanthakis, V. Lifetime risk of heart failure among participants in the framingham study. J. Am. Coll. Cardiol. 79, 250–263 (2022). 10.1016/j.jacc.2021.10.043

[44]

Ho, J. E. et al. Predicting heart failure with preserved and reduced ejection fraction. Circ. Heart Fail. 9, e003116 (2016). 10.1161/circheartfailure.115.003116

[45]

Gerber, Y. et al. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern. Med. 175, 996–1004 (2015). 10.1001/jamainternmed.2015.0924

[46]

Kotecha, D. et al. Heart failure with preserved ejection fraction and atrial fibrillation: vicious twins. J. Am. Coll. Cardiol. 68, 2217–2228 (2016). 10.1016/j.jacc.2016.08.048

[47]

Lam, C. S. et al. Atrial fibrillation in heart failure with preserved ejection fraction: association with exercise capacity, left ventricular filling pressures, natriuretic peptides, and left atrial volume. JACC Heart Fail. 5, 92–98 (2017). 10.1016/j.jchf.2016.10.005

[48]

Santhanakrishnan, R. et al. Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction. Circulation 133, 484–492 (2016). 10.1161/circulationaha.115.018614

[49]

Zakeri, R., Chamberlain, A. M., Roger, V. L. & Redfield, M. M. Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: a community-based study. Circulation 128, 1085–1093 (2013). 10.1161/circulationaha.113.001475

[50]

Sartipy, U., Dahlström, U., Fu, M. & Lund, L. H. Atrial fibrillation in heart failure with preserved, mid-range, and reduced ejection fraction. JACC Heart Fail. 5, 565–574 (2017). 10.1016/j.jchf.2017.05.001

Showing 50 of 251 references

Metrics

117

Citations

251

References

Details

Published: Aug 14, 2024
Vol/Issue: 10(1)
License: View

Authors

C

Carine E. Hamo

Department of Medicine, Stony Brook University Hospital, Stony Brook, NY, USA

C

Colette DeJong

Department of Medicine, University of California, San Francisco School of Medicine (C.D.)

N

Nick Hartshorne-Evans

L

Lars H. Lund

Department of Medicine, Unit of Cardiology, Karolinska Institute , Stockholm ,

S

Sanjiv J. Shah

Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois

S

Scott Solomon

Harvard Medical School, Division of Cardiovascular Medicine, Brigham and Women’s Hospital , Boston, MA , USA

Cite This Article

Carine E. Hamo, Colette DeJong, Nick Hartshorne-Evans, et al. (2024). Heart failure with preserved ejection fraction. Nature Reviews Disease Primers, 10(1). https://doi.org/10.1038/s41572-024-00540-y

Heart failure with preserved ejection fraction

You May Also Like